EA202191403A1 - Композиция с высокой концентрацией белка - Google Patents

Композиция с высокой концентрацией белка

Info

Publication number
EA202191403A1
EA202191403A1 EA202191403A EA202191403A EA202191403A1 EA 202191403 A1 EA202191403 A1 EA 202191403A1 EA 202191403 A EA202191403 A EA 202191403A EA 202191403 A EA202191403 A EA 202191403A EA 202191403 A1 EA202191403 A1 EA 202191403A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
protein concentration
high protein
compositions
methods
Prior art date
Application number
EA202191403A
Other languages
English (en)
Inventor
Хантер Чен
Эрика Шлезингер
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202191403A1 publication Critical patent/EA202191403A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к композициям и способам для получения композиций с высокой концентрацией терапевтического белка.
EA202191403A 2018-11-21 2019-11-21 Композиция с высокой концентрацией белка EA202191403A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
EA202191403A1 true EA202191403A1 (ru) 2021-08-09

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191403A EA202191403A1 (ru) 2018-11-21 2019-11-21 Композиция с высокой концентрацией белка

Country Status (13)

Country Link
US (1) US20200155678A1 (ru)
EP (1) EP3883542A1 (ru)
JP (1) JP2022532965A (ru)
KR (1) KR20210093976A (ru)
CN (1) CN113164378A (ru)
AU (1) AU2019384160A1 (ru)
BR (1) BR112021009463A2 (ru)
CA (1) CA3118306A1 (ru)
EA (1) EA202191403A1 (ru)
IL (1) IL283229A (ru)
MX (1) MX2021005910A (ru)
SG (1) SG11202104166QA (ru)
WO (1) WO2020106948A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する4−ヘリックスバンドルタンパク質粉末
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
EP2683362A4 (en) * 2011-03-10 2014-09-17 Univ Texas DISPERSIONS OF NANOPARTICLES OF PROTEINS
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
SG10201709555SA (en) * 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3043775B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
ES2930347T3 (es) * 2014-05-06 2022-12-13 S I I T S R L Servizio Int Imballaggi Termosaldanti Composición oleosa pulverizable basada en vitaminas liposolubles del grupo D y uso de la misma
EP3240571A4 (en) * 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies

Also Published As

Publication number Publication date
BR112021009463A2 (pt) 2021-08-10
WO2020106948A1 (en) 2020-05-28
AU2019384160A1 (en) 2021-05-27
JP2022532965A (ja) 2022-07-21
US20200155678A1 (en) 2020-05-21
CN113164378A (zh) 2021-07-23
KR20210093976A (ko) 2021-07-28
MX2021005910A (es) 2021-08-16
CA3118306A1 (en) 2020-05-28
IL283229A (en) 2021-07-29
SG11202104166QA (en) 2021-05-28
EP3883542A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201892147A1 (ru) Бициклические соединения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201791733A1 (ru) Производные 9h-пирролодипиридина
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201890572A1 (ru) Биофармацевтические композиции
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
EA202190807A1 (ru) Антитела к синуклеину
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201890177A1 (ru) Мультиспецифические связывающие белки
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA202191403A1 (ru) Композиция с высокой концентрацией белка